Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2015

Open Access 01-06-2015 | Research Article

Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma

Authors: Bozena Dobrzycka, Beata Mackowiak-Matejczyk, Katarzyna Maria Terlikowska, Bozena Kulesza-Bronczyk, Maciej Kinalski, Slawomir Jerzy Terlikowski

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

The second mitochondria-derived activator of caspase (Smac/DIABLO), vascular endothelial growth factor (VEGF), and survivin are known to play a significant role in the growth and development of numerous tumors. Serum concentrations of VEGF, survivin, and Smac/DIABLO were analyzed in 92 patients with serous ovarian cancer and 94 healthy controls. Values were correlated with clinicopathological characteristics and outcomes. The median pretreatment serum VEGF and survivin levels in patients with serous ovarian carcinoma were significantly higher, while Smac/DIABLO levels were significantly lower than that in healthy controls. Receiver operating characteristic (ROC) curve analysis showed that the best cutoff point for VEGF was determined to be 345 pg/ml; with 83 % sensitivity and 65 % specificity. For survivin, the cutoff point was 110 pg/ml and for Smac/DIABLO was 75 pg/ml, with 82 and 62 % sensitivity and 43 and 87 % specificity, respectively. In the patients group, higher VEGF and survivin levels and lower Smac/DIABLO levels in sera were significantly associated with poorer overall survival (OS) and disease-free survival (DFS). Preoperative measurement of serum VEGF, survivin, and Smac/DIABLO may be of help in early detection of serous ovarian cancer and may provide important information about the patient’s outcome and prognosis.
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://​globocan.​iarc.​fr, accessed on 21 August 2014.
2.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRefPubMed
3.
Reports based on data of National Cancer Registry. The Maria Sklodowska-Curie Memorial Cancer Center. Department of Epidemiology and Cancer Prevetion, National Cancer Registry 2011 [http://​epid.​coi.​waw.​pl/​krn].
4.
Legge F, Ferrandina G, Salutari V, Scambia G. Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol. 2005;16 Suppl 4:iv95–101.PubMed
5.
Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 2001;26:61–6.CrossRefPubMed
6.
7.
Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, et al. Survivin-biology and potential as a therapeutic target in oncology. Onco Targets Ther. 2013;6:1453–62.CrossRefPubMedPubMedCentral
8.
Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000–5.CrossRefPubMed
9.
Yu L, Deng L, Li J, Zhang Y, Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013;128(2):391–6.CrossRefPubMed
10.
11.
Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet. 2000;70:209–62.CrossRef
12.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRef
13.
Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.CrossRefPubMed
14.
Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A, et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer. 2009;19 Suppl 2:S44–8.CrossRefPubMed
15.
No JH, Jeon YT, Kim YB, Song YS. Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer. Gynecol Obstet Invest. 2011;71(2):136–40.CrossRefPubMed
16.
17.
Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35(7):553–62.CrossRefPubMed
18.
19.
Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol. 2000;17(1):149–52.PubMed
20.
Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol. 1998;92(3):360–3.PubMed
21.
Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, Ciampi B, Prontera C, et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 1999;19(2B):1401–5.PubMed
22.
Chen CA, Cheng WF, Lee CN, Chen TM, Kung CC, Hsieh FJ, et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol. 1999;74(2):235–40.CrossRefPubMed
23.
Oehler MK, Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res. 2000;20(6D):5109–12.PubMed
24.
Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193–7.PubMed
25.
Harlozinska A, Sedlaczek P, Kulpa J, Grybos M, Wójcik E, Van Dalen A, et al. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res. 2004;24(2C):1149–57.PubMed
26.
Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103(2):512–7.CrossRefPubMed
27.
28.
Sui L, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K, Tokuda M. Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. Oncol Rep. 2006;15:773–8.PubMed
29.
Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS, et al. Survivin expression in ovarian cancer. Exp Oncol. 2007;29:121–5.PubMed
30.
Chen L, Liang L, Yan X, Liu N, Gong L, Pan S, et al. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23(2):256–63.CrossRefPubMed
31.
Qian X, Xi X, Li L. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol. 2011;19(2):126–32.CrossRefPubMed
32.
Guney N, Soydine HO, Derin D, Tas F, Camlica H, Duranyildiz D, et al. Serum and urine survivin levels in breast cancer. Med Oncol. 2006;23(3):335–9.CrossRefPubMed
33.
Chang JT, Wong FH, Liao CT, Chen IH, Wang HM, Cheng AJ. Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem. 2004;50(7):1261–4.CrossRefPubMed
34.
Kehinde EO, Maghrebi MA, Anim JT. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol. 2008;15(2):3967–74.PubMed
35.
Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003;278(25):23130–40.CrossRefPubMed
36.
Dobrzycka B, Terlikowski SJ, Bernaczyk PS, Garbowicz M, Niklinski J, Chyczewski L, et al. Prognostic significance of smac/DIABLO in endometrioid endometrial cancer. Folia Histochem Cytobiol. 2010;48(4):678–81.PubMed
37.
Sekimura A, Konishi A, Mizuno K, Kobayashi Y, Sasaki H, Yano M, et al. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol Rep. 2004;11(4):797–802.PubMed
38.
Mizutani Y, Katsuoka Y, Bonavida B. Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer. Int J Oncol. 2012;40(4):1246–50.PubMedPubMedCentral
Metadata
Title
Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma
Authors
Bozena Dobrzycka
Beata Mackowiak-Matejczyk
Katarzyna Maria Terlikowska
Bozena Kulesza-Bronczyk
Maciej Kinalski
Slawomir Jerzy Terlikowski
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3050-x

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue

Review

Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target

Research Article

Downregulation of Id2 increases chemosensitivity of glioma

Research Article

Associations of polymorphisms in microRNAs with female breast cancer risk in Chinese population

Research Article

Nicotinamide induces apoptosis of F9 mouse teratocarcinoma stem cells by downregulation of SATB1 expression

Research Article

miR-23a suppresses proliferation of osteosarcoma cells by targeting SATB1

Research Article

Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits